Finanzen von Q32 Bio Inc (QTTB)QTTBQ32 Bio Inc

Evaluating the bottom line, Q32 Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 72.14%, provide a clear picture of how effectively QTTB converts its operational activities into shareholder value.

In the context of the broader market, QTTB competes directly with industry leaders such as BIVI and APUS. With a market capitalization of $267.04M, it holds a leading position in the sector. When comparing efficiency, QTTB's gross margin of N/A stands against BIVI's N/A and APUS's N/A. Such benchmarking helps identify whether Q32 Bio Inc is trading at a premium or discount relative to its financial performance.

The company has a forward P/E ratio of 0, indicating that it is expected to become profitable soon, with projected revenues of $53.7 million in Q4 2025, which could significantly improve its financial standing.